Ann Lab Med.  2020 Jan;40(1):7-14. 10.3343/alm.2020.40.1.7.

Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting

Affiliations
  • 1Department of Laboratory Medicine, Chung Ang University Hospital, Seoul, Korea.
  • 2Department of Laboratory Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. pwpark@gilhospital.com
  • 3Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, Korea.
  • 4Department of Emergency Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Abstract

BACKGROUND
Rapid and accurate diagnosis of acute myocardial infarction (AMI) is critical for initiating effective treatment and achieving better prognosis. We investigated the performance of copeptin for early diagnosis of AMI, in comparison with creatine kinase myocardial band (CK-MB) and troponin I (TnI).
METHODS
We prospectively enrolled 271 patients presenting with chest pain (within six hours of onset), suggestive of acute coronary syndrome, at an emergency department (ED). Serum CK-MB, TnI, and copeptin levels were measured. The diagnostic performance of CK-MB, TnI, and copeptin, alone and in combination, for AMI was assessed by ROC curve analysis by comparing the area under the curve (AUC). Sensitivity, specificity, negative predictive value, and positive predictive value of each marker were obtained, and the characteristics of each marker were analyzed.
RESULTS
The patients were diagnosed as having ST elevation myocardial infarction (STEMI; N=43), non-ST elevation myocardial infarction (NSTEMI; N=25), unstable angina (N=78), or other diseases (N=125). AUC comparisons showed copeptin had significantly better diagnostic performance than TnI in patients with chest pain within two hours of onset (AMI: P=0.022, ≤1 hour; STEMI: P=0.017, ≤1 hour and P=0.010, ≤2 hours). In addition, TnI and copeptin in combination exhibited significantly better diagnostic performance than CK-MB plus TnI in AMI and STEMI patients.
CONCLUSIONS
The combination of TnI and copeptin improves AMI diagnostic performance in patients with early-onset chest pain in an ED setting.

Keyword

Acute myocardial infarction; Copeptin; Troponin I; Creatine kinase myocardial band; Performance; ST elevation myocardial infarction; Non-ST elevation myocardial infarction

MeSH Terms

Acute Coronary Syndrome
Angina, Unstable
Area Under Curve
Chest Pain
Creatine Kinase
Diagnosis
Early Diagnosis*
Emergencies*
Emergency Service, Hospital*
Humans
Myocardial Infarction*
Prognosis
Prospective Studies
ROC Curve
Sensitivity and Specificity
Troponin I
Creatine Kinase
Troponin I

Figure

  • Fig. 1 ROC curves for CK-MB, TnI, and copeptin according to the time of chest pain onset in AMI patients. The ROC curve plots sensitivity on the Y-axis and (1-specificity) on the X-axis. The area under the curve (AUC) of each marker is presented in each graph. Copeptin as a single marker was superior to CK-MB within six hours [(A)–(C)] and to TnI within two hours [(A) & (B)] in the STEMI group (P<0.05). Copeptin showed better diagnostic performance than CK-MB within two hours [(G) & (H)] and TnI within one hour in the AMI group (G) (P<0.05).Abbreviations: STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; AMI, acute myocardial infarction; CK-MB, creatine kinase myocardial band; TnI, troponin I.

  • Fig. 2 ROC curves for combined markers according to the time of chest pain onset in AMI patients. A combination of the three markers showed the highest ROC curves in all patient groups. Copeptin plus TnI showed better diagnostic performance than TnI plus CK-MB in the STEMI [(A)–(C)] and AMI [(G)–(I)] groups (P<0.05).Abbreviations: STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; AMI, acute myocardial infarction; CK-MB, creatine kinase myocardial band; TnI, troponin I; copep, copeptin.


Cited by  1 articles

흉통과 경한 트로포닌 I 상승을 보이는 환자에서, 비-ST분절 상승 급성 심근 경색증을 진단하기 위한 코펩틴의 유용성 평가
Jihoon Kim, Jimyung Kim, Jinsook Lim, Seon Young Kim, Gye Cheol Kwon, Sun Hoe Koo
Lab Med Online. 2022;12(1):20-25.    doi: 10.47429/lmo.2022.12.1.20.


Reference

1. Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department. JAMA Intern Med. 2015; 175:67–75. PMID: 25401720.
2. Hajar R. Evolution of myocardial infarction and its biomarkers: a historical perspective. Heart Views. 2016; 17:167–172. PMID: 28400945.
3. Plebani M, Antonelli G, Zaninotto M. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitive cardiac troponin. Intern Emerg Med. 2017; 12:143–145. PMID: 28210831.
4. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008; 19:43–49. PMID: 18291667.
5. Slagman A, Searle J, Müller C, Möckel M. Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction. Clin Chem. 2015; 61:1273–1282. PMID: 26341999.
6. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol. 2013; 62:150–160. PMID: 23643595.
7. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37:267–315. PMID: 26320110.
8. Reinstadler SJ, Klug G, Feistritzer HJ, Metzler B, Mair J. Copeptin testing in acute myocardial infarction: ready for routine use? Dis Markers. 2015; 2015:614145. PMID: 25960596.
9. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007; 37:145–152. PMID: 17217381.
10. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007; 28:219–226. PMID: 17515850.
11. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009; 66:799–808. PMID: 20035506.
12. Möckel M, Searle J. Copeptin-marker of acute myocardial infarction. Curr Atheroscler Rep. 2014; 16:421. PMID: 24844208.
13. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52:112–119. PMID: 16269513.
14. Marston NA, Shah KS, Mueller C, Neath SX, Christenson RH, McCord J, et al. Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. Emerg Med J. 2016; 33:23–29. PMID: 26105583.
15. Lipinski MJ, Escárcega RO, D'Ascenzo F, Magalhães MA, Baker NC, Torguson R, et al. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol. 2014; 113:1581–1591. PMID: 24731654.
16. Boeddinghaus J, Reichlin T, Nestelberger T, Twerenbold R, Meili Y, Wildi K, et al. Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin. Clin Res Cardiol. 2017; 106:457–467. PMID: 28150185.
17. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009; 54:60–68. PMID: 19555842.
18. MacRae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem. 2006; 52:812–818. PMID: 16556688.
19. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol. 2007; 128:282–286. PMID: 17638663.
20. Shin H, Jang BH, Lim TH, Lee J, Kim W, Cho Y, et al. Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: a systematic review and meta-analysis. PloS One. 2018; 13:e0200379. PMID: 29979797.
21. Mueller C, Möckel M, Giannitsis E, Huber K, Mair J, Plebani M, et al. Use of copeptin for rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2017; 2048872617710791.
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr